delmaine donson
Mainz Biomed (NASDAQ:MYNZ) said it has exercised its option on Uni Targeting Research AS to acquire all previously licensed intellectual property (IP) for its ColoAlert colorectal cancer (CRC) screening test, which is sold in Europe.
In addition, Mainz also exercised its exclusive right option with SOCPRA Sciences Sante et Humaines (SOCPRA) to purchase intellectual property, including a pending patent, linked to a portfolio of novel gene expression (mRNA) biomarkers.
These biomarkers have shown the ability to detect CRC lesions, including advanced adenomas (AAs), a type of precancerous polyp often attributed to the disease, according to the company.
“Securing full ownership of intellectual property is an integral part of our growth strategy, as it streamlines administration, reduces expenses per test, and gives us the opportunity to increase corporate development activities,” said Mainz CEO, Guido Baechler.
Mainz noted that it is evaluating the mRNA biomarkers acquired from SOCPRA in the ColoFuture and eAArly DETECT studies (US and Europe), testing the potential for integrating these biomarkers into ColoAlert.
The eAArly DETECT study is on track to complete enrollment in the first quarter of 2023, with results expected in the first half of 2023.
Based on the results, Mainz said it will decide on the integration of the biomarkers into the ReconAAsense study, which is on track to enroll patients in the summer of 2023, with results expected in 2025.
MYNZ +5.74% at $7.35 before marketing on February 21
